QUÉBEC CITY, Oct. 23, 2018 /PRNewswire/ -- GenePOC Inc., member of the Debiopharm Group, is proud to announce the approval by Health Canada and the launch of its GenePOC CDiff assay to be used with ...
A doctor checks on a patient laying in a hospital bed. The use of a NAAT for diagnosing Clostridium difficile infection demonstrated a significant reduced length of stay for patients compared with a ...
This study explores the effectiveness of toxin testing in predicting Clostridioides difficile infection (CDI) outcomes, revealing that patients with negative toxin results were less likely to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback